Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., trading under the ticker LACQ, filed an 8-K current report with the SEC on November 21, 2024, under accession number 0001493152-24-047149. The company reached public markets through Leisure Acquisition Corp., a blank-check vehicle that completed its IPO in 2019 and subsequently merged with Ensysce, a biotechnology firm focused on abuse-deterrent drug formulations. Operating in the pharmaceutical and life sciences sector, Ensysce has been a post-merger public company navigating the commercial development of its proprietary drug-delivery technology. The November 2024 filing reflects ongoing disclosure obligations stemming from the original SPAC transaction structure. For complete filing history, merger documentation, and real-time SPAC analytics on LACQ and hundreds of other vehicles, sign up for full data access at SpacDesk.